Aruvant Sciences

Will Chou, M.D., CEO

New York, NY


Virtual Presentation

Aruvant Sciences, a part of the Roivant family of companies, is a clinical-stage biopharmaceutical company committed to developing and commercializing transformative gene therapies for rare diseases. We have a talented team with extensive experience in the development, manufacturing, and commercialization of gene therapy products. The company’s lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for sickle cell disease (SCD). Preliminary clinical data from the ongoing Phase I/II study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial of ARU-1801 in severe SCD. Our second product, ARU-2801, is a one-time, adeno-associated virus (AAV) gene therapy designed to deliver potentially curative efficacy to patients with hypophosphatasia without the limitations of chronic administration.

By using this website you agree to accept our Privacy Policy and Terms & Conditions